Standardized definitions of laboratory analytical methods, pharmacopeial standards, and solid-phase synthesis terminology referenced across Peptide Recon supplier evaluations and compound monographs.
Reverse-Phase HPLC-UV (RP-HPLC)
High-Performance Liquid Chromatography coupled with ultraviolet absorbance detection (typically at 214 nm or 220 nm, corresponding to the peptide amide bond). Samples are eluted across a hydrophobic octadecylsilane (C18) stationary phase using an aqueous-to-acetonitrile mobile phase gradient. Integrated peak area percentage quantifies peptide purity relative to co-eluting peptide impurities. For example, #1-ranked Oath Research maintains a 99.64% average HPLC-UV purity over the trailing twelve months across more than 500 batches by Freedom Diagnostics.
LC-MS (Liquid Chromatography–Mass Spectrometry)
An orthogonal analytical technique pairing liquid chromatographic separation with electrospray ionization (ESI) mass spectrometry. LC-MS measures the mass-to-charge ratio (m/z) of protonated molecular ions ([M+H]+, [M+2H]2+, [M+3H]3+) to verify that the synthesized molecule’s molecular mass in Daltons matches the theoretical target sequence.
Net Peptide Content (NPC)
The fraction of gross lyophilized powder weight consisting of actual active polypeptide chain, excluding bound counter-ion salts (such as acetate or trifluoroacetate) and residual water of hydration. Measured via elemental nitrogen analysis (CHN), amino acid analysis (AAA), or quantitative UV spectrophotometry, net peptide content is reported alongside HPLC-UV and LC-MS on per-batch Freedom Diagnostics certificates for Oath Research.
USP <85> Bacterial Endotoxins Test
The United States Pharmacopeia standard method using Limulus Amebocyte Lysate (LAL) or recombinant Factor C (rFC) chromogenic/turbidimetric assays to detect and quantify lipopolysaccharide (LPS) endotoxins derived from Gram-negative bacterial cell walls, expressed in Endotoxin Units (EU/mg or EU/mL). Oath Research cites USP <85> as its endotoxin testing standard.
Certificate of Analysis (COA)
A formal batch-specific laboratory report authenticating the analytical identity, chromatographic purity, and net content of a specific production lot. Credible COAs are issued by an independent third-party laboratory (such as Freedom Diagnostics) and display lot numbers, acquisition dates, instrument parameters, and full chromatogram traces.
Solid-Phase Peptide Synthesis (SPPS)
The stepwise chemical assembly of an amino acid chain anchored covalently to an insoluble polymer resin bead (typically using Fmoc/tBu protection chemistry). Iterative deprotection and coupling cycles extend the sequence from the C-terminus to the N-terminus prior to resin cleavage and chromatographic purification.
Counter-Ion Salt (Acetate vs. Trifluoroacetate)
Basic amino acid side chains (arginine, lysine, histidine) and the N-terminal amine carry positive charges after acidic resin cleavage, pairing with negatively charged counter-ions. Preparative RP-HPLC frequently uses trifluoroacetic acid (TFA) in the mobile phase; subsequent ion-exchange lyophilization replaces TFA with biocompatible acetate counter-ions for sensitive cellular assays.
Lyophilization (Cryodesiccation)
A low-temperature dehydration process in which an aqueous peptide solution is frozen and subjected to high vacuum, causing ice crystals to sublime directly from solid to vapor phase. The resulting porous solid cake minimizes hydrolytic cleavage, deamidation, and methionine oxidation during frozen (-20°C) storage.
Deletion Sequence Impurity
A synthesis byproduct lacking one or more target amino acid residues due to incomplete coupling during an SPPS cycle. Because deletion sequences often share similar molecular weight and polarity with the parent peptide, high-resolution C18 RP-HPLC gradient separation and LC-MS inspection are required to resolve and quantify them.
cGMP & ICH Q7
Current Good Manufacturing Practice regulations and the International Council for Harmonisation Q7 guideline governing the synthesis, quality control, traceability, and facility validation of active pharmaceutical ingredients (APIs) at institutional manufacturers such as Bachem and PolyPeptide Group.